Contents

From the Chairman and the CEO 03

amfAR in 2010: Selected Accomplishments 04

Grants, Fellowships, and Awards 06

  Research Grants
  TREAT Asia Awards
  MSM Initiative Awards
  Public Policy Awards

Message from the Treasurer and the Chair of the Finance and Budget Committee 14

Financial Highlights 15

Leadership and Advisory Committees 18

  Board of Trustees
  Scientific Advisory Committee
  Program Advisory Council
  Management Group
From the Chairman and the CEO

As we commemorate amfAR’s 25 years in the vanguard of the global response to HIV/AIDS, we find ourselves energized by a surge of momentum and vibrancy in the field of AIDS research. We sometimes struggle to explain the nature of this sea change that has made us more optimistic than ever before about our chances of finding a cure. Here’s one way to think about it.

For many years, AIDS research focused almost exclusively on trying to define the enemy—mapping out the way in which HIV invaded the human body and set about destroying the immune system. It was a little like shining a flashlight in the dark. What you’re able to see appears with great clarity. The trouble is, you’re never really sure how vast the darkness is.

The research progress we’ve made in the last few years has effectively switched on the lights. Now, at last, we can see where we’re going and chart a path forward. In fact, several potential pathways are now laid out before us. What was deemed naïve and unrealistic—even unmentionable—just a few years ago is now within the realm of possibility.

To capitalize on this momentum, in 2010 we launched a new research consortium for the express purpose of bringing teams of top scientists together to work collaboratively on the search for a cure. The greatest tribute we can pay to all who have dedicated their lives and their resources to our cause is to redouble our efforts to bring this epidemic to an end. With your continued partnership and generous support, we will do precisely that.

Kenneth Cole
Chairman of the Board

Kevin Robert Frost
Chief Executive Officer

amfAR, The Foundation for AIDS Research, is dedicated to ending the global AIDS epidemic through innovative research.
Accelerating the Search for a Cure

Placing the search for a cure for HIV/AIDS firmly at the center of its research efforts, in May 2010 amfAR launched the Research Consortium for HIV Eradication (ARCHE), a bold new grant program supporting collaborative teams of biomedical researchers exploring the barriers to and potential for eradicating HIV infection. With first-round funding of more than $1 million, ARCHE is supporting four groups of investigators who are exploring issues that are considered central to HIV eradication—work that is already starting to change the direction of AIDS research.

Improving Treatment for Children

HIV-positive children consistently face greater disadvantages than adults when it comes to antiretroviral therapy. With the aim of improving access to higher quality pediatric HIV/AIDS care in Asia, amfAR's TREAT Asia program launched a two-year initiative to develop strategies to support lifelong care for HIV-positive children and generate clinical data that will inform pediatric treatment guidelines.
Harnessing the Potential of Gene Therapy

amfAR announced its first ever awards for cutting-edge gene therapy research in February 2010, supporting a broad range of approaches to HIV prevention, treatment, and cure. These projects aim to subvert the process of HIV infection and eradicate the virus through strategies that thwart HIV directly or block its access to the cells it needs to replicate. Grantees are pursuing innovative approaches such as using a type of molecular scissors to lethally cut up the HIV genome; exploring a new and more efficient means of delivering gene therapy into a patient’s body; and engineering and testing a variety of immune interventions that could be developed into a vaccine.

Expanding the HIV Knowledge Base

During 2010, amfAR-funded investigators continued to advance and expand our understanding of HIV, publishing 35 peer-reviewed scientific papers in prestigious journals such as *Nature Medicine* and the *Journal of the American Medical Association*.

Bringing a National AIDS Strategy to Life

When amfAR’s public policy office opened in 1991, the Foundation identified the creation of a U.S. national HIV/AIDS strategy as a top goal. Finally, after two decades of unrelenting advocacy by amfAR and other AIDS organizations, President Obama unveiled the National HIV/AIDS Strategy in July 2010, setting specific goals for reducing HIV incidence, increasing access to care, and addressing health disparities.

Toppling the Travel Ban

After years of persistent advocacy by amfAR and like-minded organizations, the U.S. government finally removed the ban on HIV-positive foreign visitors and immigrants on January 4, 2010. Three days later, the arrival of an HIV-positive man from Holland heralded a new era of unimpeded travel for people living with HIV and signaled the demise of a ban that was instituted in 1987.

Tailoring Training

The expansion of HIV/AIDS treatment throughout Asia has brought hope to millions living with the virus, but it has also created a host of challenges for HIV clinicians and researchers as they try to stay abreast of the latest developments in this complex and rapidly changing field. To address the diversity of training needs across this vast region, TREAT Asia launched an innovative education program in 2010 that provides training in areas such as pediatrics research and lab capacity development tailored to the needs of specific settings.

Meeting the HIV Needs of MSM

From South Africa to Ecuador and Ukraine to Vietnam, efforts to prevent and treat HIV/AIDS among men who have sex with men (MSM) in low- and middle-income countries received a substantial boost in 2010 from amfAR’s MSM Initiative. Through the Initiative—which concentrates its efforts in countries where HIV among MSM is severely neglected—amfAR made 41 community awards to grassroots groups in 35 countries, bringing the number of awards since the program’s inception in 2007 to 101. Many of the 2010 projects built on work funded by previous awards, a testament to the growing effectiveness of MSM Initiative grantees.

Standing Up for Human Rights

MSM in many parts of the world face increasing levels of homophobic and transphobic rhetoric and violence, which impede access to vital HIV prevention, treatment, and care services for marginalized populations that are often at high risk of infection. During 2010, amfAR spoke out frequently, publicly, and emphatically in support of the human rights that are inextricably linked with public health and the fight against HIV/AIDS.
Optimizing Treatment

CCR5 heterogeneity and mechanism of viral resistance to CCR5 inhibitors
Reem Berro, Ph.D.
Weill Medical College of Cornell University
New York, NY
$125,000

Contribution of E3 ubiquitin ligase activity to HIV-1 restriction by TRIM5
Felipe Diaz-Griffero, Ph.D.
Albert Einstein College of Medicine of Yeshiva University
Bronx, NY
$80,000 (Phase II Funding)

Structural mechanisms for nuclear export of HIV-1 REV by CRM1
Xiuhua Dong, M.D., Ph.D.
University of Texas Southwestern Medical Center at Dallas
Dallas, TX
$125,000

Preventing HIV Transmission

Evaluation of the immunogenicity of “evolved” stable HIV-1 Env trimers
Rogier Sanders, Ph.D.
Academic Medical Center of the University of Amsterdam
Amsterdam, Netherlands
$62,675 (Phase II)

Biophysical and structural studies of the HIV integrase DNA complex
Kushol Gupta, Ph.D.
University of Pennsylvania School of Medicine
Philadelphia, PA
$125,000 (2008)

AMFAR RESEARCH CONSORTIUM ON HIV ERADICATION (ARCHE)

Inflammation and HIV persistence
Principal Investigator: Joseph McCune, M.D., Ph.D.
University of California, San Francisco
San Francisco, CA
$360,000

Collaborating Investigator: Steven Deeks, M.D.
University of California, San Francisco
San Francisco, CA

Characterizing and targeting persistent HIV viremia
Principal Investigator: Sarah Palmer, Ph.D.
Swedish Institute for Infectious Disease Control, Karolinska Institute
Solina, Sweden
$360,000

Collaborating Investigator: Frederick Hecht, M.D.
University of California, San Francisco
San Francisco, CA

Using approved drugs to target latent HIV
Principal Investigator: Robert F. Siliciano, M.D., Ph.D.
Johns Hopkins University
Baltimore, MD
$360,000

Collaborating Investigator: Janice E. Clements, Ph.D.
Johns Hopkins University
Baltimore, MD

Quantitating virus in patients receiving either non-ablative or total ablative treatment
Principal Investigator: John Zaia, M.D.
Beckman Research Institute of City of Hope
Duarte, CA
$120,000

MATHILDE KRIM FELLOWS IN BASIC BIOMEDICAL RESEARCH

Pursuing HIV Eradication

Studies of HIV-1 latency and reactivation using a novel ex-vivo model
Alberto Bosque, Ph.D.
University of Utah
Salt Lake City, UT
$125,000 (2009)

Macrophage-T cell interactions in formation of the HIV-1 reservoir
Fedde Groot, Ph.D.
University of Oxford
Oxford, United Kingdom
$124,782 (2009)

Novel post-transcriptional mechanisms of HIV-1 latency and reactivation
Kara Lassen, Ph.D.
The J. David Gladstone Institutes
San Francisco, CA
$102,340 (2008)

Using approved drugs to target latent HIV
Principal Investigator: Robert F. Siliciano, M.D., Ph.D.
Johns Hopkins University
Baltimore, MD
$360,000

Collaborating Investigator: Janice E. Clements, Ph.D.
Johns Hopkins University
Baltimore, MD

Quantitating virus in patients receiving either non-ablative or total ablative treatment
Principal Investigator: John Zaia, M.D.
Beckman Research Institute of City of Hope
Duarte, CA
$120,000

Using approved drugs to target latent HIV
Principal Investigator: Robert F. Siliciano, M.D., Ph.D.
Johns Hopkins University
Baltimore, MD
$360,000

Collaborating Investigator: Janice E. Clements, Ph.D.
Johns Hopkins University
Baltimore, MD

Quantitating virus in patients receiving either non-ablative or total ablative treatment
Principal Investigator: John Zaia, M.D.
Beckman Research Institute of City of Hope
Duarte, CA
$120,000

Characterization of transportin-SR2 mediated nuclear import of HIV
Jan De Rijck, Ph.D.
Katholieke Universiteit Leuven
Leuven, Belgium
$125,000 (2009)

Morphogenesis and storage of HIV-1 particles
Nolwenn Jouvenet, Ph.D.
Aaron Diamond AIDs Research Center
New York, NY
$125,000 (2008)

Ultrapotent inhibitors of wild-type and multi-drug resistant HIV
Bruno Marchand, Ph.D.
University of Missouri-Columbia
Columbia, MO
$125,000 (2008)

Maintenance of drug resistance mutations and HIV-1 evolutionary adaptation
Morgane Rolland, Ph.D.
University of Washington
Seattle, WA
$125,000 (2008)

Mechanisms of Vpx and Vpr targeted restriction factors
Thomas Gramberg, Ph.D.
New York University School of Medicine
New York, NY
$125,000

Biophysical and structural studies of the HIV integrase DNA complex
Kushol Gupta, Ph.D.
University of Pennsylvania School of Medicine
Philadelphia, PA
$125,000 (2008)

A chemical campaign to identify HIV-1 entry inhibitors
Navid Madani, Ph.D.
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA
$125,000 (2009)

Quantitating virus in patients receiving either non-ablative or total ablative treatment
Principal Investigator: John Zaia, M.D.
Beckman Research Institute of City of Hope
Duarte, CA
$120,000

Morphogenesis and storage of HIV-1 particles
Nolwenn Jouvenet, Ph.D.
Aaron Diamond AIDs Research Center
New York, NY
$125,000 (2008)

Ultrapotent inhibitors of wild-type and multi-drug resistant HIV
Bruno Marchand, Ph.D.
University of Missouri-Columbia
Columbia, MO
$125,000 (2008)

Maintenance of drug resistance mutations and HIV-1 evolutionary adaptation
Morgane Rolland, Ph.D.
University of Washington
Seattle, WA
$125,000 (2008)

A chemical campaign to identify HIV-1 entry inhibitors
Navid Madani, Ph.D.
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA
$125,000 (2009)

Preventing HIV Transmission

Generation of stable HIV-1 Env trimers through virus evolution
Rogier Sanders, Ph.D.
Academic Medical Center, University of Amsterdam
Amsterdam, Netherlands
$125,000 (2008) (Phase I)

A chemical campaign to identify HIV-1 entry inhibitors
Navid Madani, Ph.D.
Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA
$125,000 (2009)
RESEARCH FELLOWSHIPS

Pursuing Eradication

Direct injectable cell targeting vectors for improved HIV gene therapy
Joseph Anderson, Ph.D.
University of California, Davis
Davis, CA
$125,000

Creation of a synergistic immune response to HIV by gene therapy
Alejandro Balazs, Ph.D.
California Institute of Technology
Pasadena, CA
$125,000

Engineer pluripotent stem cell derived NK cells to kill HIV infection
Zhenya Ni, Ph.D.
University of Minnesota
Minneapolis, MN
$125,000

In vivo modeling of HIV persistence and its eradication
Paul Denton, Ph.D.
University of Texas Southwestern Medical Center
Dallas, TX
$125,000 (2008)

Optimizing Treatment

Identifying cellular cofactors of rhesus monkey TRIM5-alpha
Devin Christensen, Ph.D.
University of Utah
Salt Lake City, UT
$125,000 (2009)

Cellular factors required for HIV cell-to-cell transmission
Jing Jin, Ph.D.
Yale University School of Medicine
New Haven, CT
$125,000 (2009)

What they’re not telling me: Veterans, trust, and HIV management
Kristin Mattocks, Ph.D.
Yale University
New Haven, CT
$108,480 (2008)

Preventing HIV Transmission

Cell phone use among MSM in stigmatized settings: Implications for HIV
Joyce Nyoni, Ph.D.
University of Dar es Salaam
Dar es Salaam, Tanzania
$114,110 (2009)

The role of mental health issues in HIV acquisition among female drug users
Gail Gilchrist, Ph.D.
L’Institut Municipal d’Investigacio Medica
Barcelona, Spain
$124,915 (2008)

Anal intercourse, STIs, and HIV among STD clinic clients
Marjan Javanbakht, Ph.D.
University of California, Los Angeles
Los Angeles, CA
$112,193 (2007)

RESEARCH GRANTS

Pursuing HIV Eradication

Combination of CCR5Δ32 and siRNAs targeting HIV
Lung-Ji Chang, Ph.D.
University of Florida
Gainesville, FL
$120,000

Engineering and characterization of HIV-specific homing endonucleases
Keith Jerome, M.D., Ph.D.
University of Washington
Seattle, WA
$120,000

Using homologous recombination to stack genetic resistance to HIV infection
Matthew Porteus, M.D., Ph.D.
University of Texas Southwestern Medical Center
Dallas, TX
$120,000

In vivo virus persistence during suppressive therapy in the RT-SHIV model
Zandrea Ambrose, Ph.D.
University of Pittsburgh
Pittsburgh, PA
$120,000 (2008)

Animal model for controlled SIV infection
Cristian Apetrei, M.D., Ph.D.
Tulane University
New Orleans, LA
$119,687 (2008)

Autophagy and intracellular HIV in macrophages
Vojo Deretic, Ph.D.
University of New Mexico Health Sciences Center
Albuquerque, NM
$120,000 (2008)

HDAC inhibition and chromatin remodeling to disrupt proviral latency
David Margolis, M.D.
University of North Carolina at Chapel Hill
Chapel Hill, NC
$120,000 (2008)

In vivo modeling of HIV persistence and its eradication
Paul Denton, Ph.D.
University of North Carolina at Chapel Hill
Chapel Hill, NC
$63,483 (transfer) (2008)

Viral persistence in the MGT of RT-SHIV infected macaques on HAART
Miranda Xhilaga, Ph.D.
Monash University
Melbourne, Australia
$125,000 (2007)

In vivo modeling of HIV persistence and its eradication
Paul Denton, Ph.D.
University of North Carolina at Chapel Hill
Chapel Hill, NC
$120,000 (2008)

Optimizing Treatment

Identifying cellular cofactors of rhesus monkey TRIM5-alpha
Devin Christensen, Ph.D.
University of Utah
Salt Lake City, UT
$125,000 (2009)

Cellular factors required for HIV cell-to-cell transmission
Jing Jin, Ph.D.
Yale University School of Medicine
New Haven, CT
$125,000 (2009)

What they’re not telling me: Veterans, trust, and HIV management
Kristin Mattocks, Ph.D.
Yale University
New Haven, CT
$108,480 (2008)

Preventing HIV Transmission

Cell phone use among MSM in stigmatized settings: Implications for HIV
Joyce Nyoni, Ph.D.
University of Dar es Salaam
Dar es Salaam, Tanzania
$114,110 (2009)

The role of mental health issues in HIV acquisition among female drug users
Gail Gilchrist, Ph.D.
L’Institut Municipal d’Investigacio Medica
Barcelona, Spain
$124,915 (2008)

Anal intercourse, STIs, and HIV among STD clinic clients
Marjan Javanbakht, Ph.D.
University of California, Los Angeles
Los Angeles, CA
$112,193 (2007)
Optimizing Treatment

Evaluating healthy living curriculum for HIV-infected youth
*New York State HIV Research Centers Consortium Grant*
Susan Abramowitz, Ph.D.
New York University School of Medicine
New York, NY
$32,999

Effectiveness of a collaborative model of HIV primary care in the Bronx
*New York State HIV Research Centers Consortium Grant*
Carolyn Chu, M.D.
Montefiore Medical Center
Bronx, NY
$33,000

High-throughput screens for inhibitors of Vif-APOBEC3G interaction
Dana Gabuzda, M.D.
Dana-Farber Cancer Institute, Inc.
Boston, MA
$120,000 (2009)

Preventing HIV Transmission

A pilot study of a text messaging-enhanced POL HIV intervention program
Hongjie Liu, Ph.D.
Virginia Commonwealth University
Richmond, VA
$119,894 (2009)

Assessing internet users’ preferences for structural and network interventions
Willi McFarland, M.D.
San Francisco Department of Health
San Francisco, CA
$102,421 (2009)

RESEARCH AWARDS

Optimizing Treatment

HIV/AIDS and aging: Emerging issues in research, care, treatment and prevention
Judith Auerbach, Ph.D.
San Francisco AIDS Foundation
San Francisco, CA
$5,500

International consensus meeting on AIDS-related CMV retinitis
Gary N. Holland, M.D.
University of California, Los Angeles
Los Angeles, CA
$25,000

The role of PIP2 as a cofactor for HIV-1 assembly at the plasma membrane
Akira Ono, Ph.D.
University of Michigan
Ann Arbor, MI
$120,000 (2009)

Target of Vpr/Vpx Restriction
Lee Ratner, M.D., Ph.D.
Washington University School of Medicine
St. Louis, MO
$120,000 (2009)

An evolutionary approach to identifying robust antiretroviral drug targets
Sara Sawyer, Ph.D.
University of Texas at Austin
Austin, TX
$120,000 (2009)

Mistrust of evidence-based medicine affects health outcomes of Latinos
Scott Rhodes, Ph.D.
Wake Forest University Health Sciences
Winston-Salem, NC
$120,000 (2008)

Neurocognitive factors in the relationship between drug use and risky sex
Sarit Golub, Ph.D.
Research Foundation of the City of New York
Flushing, NY
$120,000 (2008)

HIV prevention efficacy beliefs about male circumcision in South Africa
Joanne Mantell, Ph.D.
HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute and Columbia University
New York, NY
$119,906 (2008)

Minority stress, social support, and sexual risk in South African MSM
Theodorus Sandfort, Ph.D.
Research Foundation for Mental Hygiene, Inc.
New York, NY
$119,836 (2008)

Epithelial injury and HIV penetration after simulated ejaculation
Craig Hendrix, M.D.
Johns Hopkins University School of Medicine
Baltimore, MD
$120,000 (2007)
TREAT Asia Grants and Awards

All projects listed below were supported by amfAR during the period October 1, 2009, to September 30, 2010. Grants funded during fiscal year 2010 but awarded in previous years are shown with the year of the award in parentheses.

ASIA PACIFIC HIV OBSERVATIONAL DATABASE (APHOD)

Matthew G. Law, Ph.D.
University of New South Wales
Coogee, Australia
$332,278 (Year 5)
$279,293 (2009–Year 4)

TREAT ASIA HIV OBSERVATIONAL DATABASE (TAHOD)

Huy Bui, Ph.D., M.D.
National Hospital of Tropical Diseases
Hanoi, Vietnam
$15,000 (Year 5)

Yi-Ming Chen, M.D., Sc.D.
National Yang-Ming University
Taipei, China
$15,000 (Year 5)
$15,000 (2009–Year 4)
$1,920 (2009–Tuberculosis Expansion of Work–Year 4)

Jun Yong Choi, M.D., Ph.D.
Yonsei University College of Medicine
Seoul, South Korea
$15,000 (Year 5)
$15,000 (2009–Year 4)
$1,280 (2009–Tuberculosis Expansion of Work–Year 4)

Rossana Ditangco, M.D.
Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City, Philippines
$15,000 (Year 5)
$15,000 (2009–Year 4)
$1,200 (2009–Tuberculosis Expansion of Work–Year 4)

Adeeba Kamarulzaman, F.R.A.C.P.
University of Malaya
Kuala Lumpur, Malaysia
$15,000 (Year 5)
$15,000 (2009–Year 4)
$6,720 (2009–Tuberculosis Expansion of Work–Year 4)

Nagalingeswaran Kumarasamy, M.D., M.B.B.S, Ph.D.
YRG Centre for AIDS Research and Education, VHS
Chennai, India
$15,000 (Year 5)
$15,000 (2009–Year 4)
$960 (2009–Tuberculosis Expansion of Work–Year 4)

Christopher Lee, M.B.B.S., M.R.C.P.
Sungai Buloh Hospital
Sungai Buloh, Malaysia
$15,000 (Year 5)
$15,000 (2009–Year 4)
$2,880 (2009–Tuberculosis Expansion of Work–Year 4)

Patrick Li, M.B.B.S.
Queen Elizabeth Hospital
Hong Kong SAR, China
$15,000 (Year 5)
$15,000 (2009–Year 4)

Poh Lian Lim, M.D., M.P.H.
Tan Tock Seng Hospital
Singapore
$15,000 (Year 5)
$15,000 (2009–Year 4)
$640 (2009–Tuberculosis Expansion of Work–Year 4)

Tuti Parwati Merati, M.D.
Udayana University School of Medicine
Denpasar, Indonesia
$15,000 (Year 5)
$15,000 (2009–Year 4)
$6,500 (2009–Tuberculosis Expansion of Work–Year 4)

Shinichi Oka, M.D.
National Center for Global Health and Medicine
Shinjuku, Japan
$15,000 (Year 5)
$15,000 (2009–Year 4)
$880 (2009–Tuberculosis Expansion of Work–Year 4)

Sanjay Pujari, M.D.
Institute of Infectious Diseases
Pune, India
$15,000 (Year 5)
$15,000 (2009–Year 4)
$3,280 (2009–Tuberculosis Expansion of Work–Year 4)

Thira Sirisanthana, M.D.
Chiang Mai University
Chiang Mai, Thailand
$15,000 (Year 5)
$15,000 (2009–Year 4)
$4,880 (2009–Tuberculosis Expansion of Work–Year 4)

Somnuek Sungkanupaph, M.D.
Ramathibodi Hospital, Mahidol University
Bangkok, Thailand
$15,000 (Year 5)
$15,000 (2009–Year 4)
$3,200 (2009–Tuberculosis Expansion of Work–Year 4)

Pham Thy, M.D.
Bach Mai Hospital
Hanoi, Vietnam
$15,000 (Year 5)

Saphonn Vonthanak, M.D., Ph.D.
National Center for HIV/AIDS, Dermatology and STDs
Phnom Penh, Cambodia
$15,000 (Year 5)
$15,000 (2009–Year 4)
$7,600 (2009–Tuberculosis Expansion of Work–Year 4)

Evy Yunihasututi, M.D.
Cipto Mangunkusumo General Hospital
Jakarta Pusat, Indonesia
$15,000 (Year 5)
$15,000 (2009–Year 4)
$12,800 (2009–Tuberculosis Expansion of Work–Year 4)

Fujie Zhang, M.D.
Beijing Ditan Hospital
Beijing, China
$15,000 (Year 5)
$15,000 (2009–Year 4)

Identifying biomarkers of anal intraepithelial neoplasia in Thai MSM

Jintanat Ananworanich, M.D., and Nittaya Phanuphak, M.D.
HIV-NAT/Thai Red Cross AIDS Research Center
Bangkok, Thailand
$92,000 (Year 2)
$52,000 (Supplemental Funding to Year 1)
$60,000 (2009 Year 1)

International collaboration for testing discordant subtypes

Yi-Ming Chen, M.D., Sc.D.
National Yang-Ming University
Taipei, China
$20,000

Clinical epidemiology of cancer among PLHA in Taiwan

Yi-Ming Chen, M.D., Sc.D.
National Yang-Ming University
Taipei, China
$50,000 (Year 3)
$70,000 (2009–Year 2)

Multidisciplinary services to enhance HIV testing and linkage to care among MSM

Prapan Phanuphak, M.D., Ph.D.
HIV-NAT/Thai Red Cross AIDS Research Center
Bangkok, Thailand
$235,040

Glomerular filtration rate estimation in HIV-infected Thai patients

Prapan Phanuphak, M.D., Ph.D.
HIV-NAT/Thai Red Cross AIDS Research Center
Bangkok, Thailand
$20,000

Determinants of HIV disease progression and treatment outcomes among MSM in the Philippines

Rossana Ditangco, M.D.
Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City, Philippines
$20,000
### AUSTRALIAN HIV OBSERVATIONAL DATABASE (AHOD)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City</th>
<th>State</th>
<th>Funding Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Debra Allen, M.B.Ch.B., Dip Med.</td>
<td>Northern Sydney Central Coast Area Health Services</td>
<td>Gosford, Australia</td>
<td>$1,275 (Year 5)</td>
<td>$1,200 (2009–Year 4)</td>
</tr>
<tr>
<td>Katherine Brown, M.D.</td>
<td>South East Sydney Illawarra Area Health Service</td>
<td>Warrawong, Australia</td>
<td>$1,500 (Year 5)</td>
<td>$1,725 (2009–Year 4)</td>
</tr>
<tr>
<td>Andrew Carr, M.D.</td>
<td>St. Vincent’s Hospital Sydney</td>
<td>Darlinghurst, Australia</td>
<td>$7,200 (Year 5)</td>
<td>$7,500 (2009–Year 4)</td>
</tr>
<tr>
<td>John Chua, M.B.B.S., B.S.M.D.</td>
<td>Gold Coast Health Service District</td>
<td>Miami, Australia</td>
<td>$7,500 (Year 5)</td>
<td>$7,500 (2009–Year 4)</td>
</tr>
<tr>
<td>William Donohue, M.B.B.S.</td>
<td>University of Adelaide, Care and Prevention Program</td>
<td>Adelaide, Australia</td>
<td>$2,100 (Year 5)</td>
<td>$2,100 (2009–Year 4)</td>
</tr>
<tr>
<td>Jennifer Hoy, M.B.B.S.</td>
<td>Victorian HIV Service, Alfred Hospital</td>
<td>Melbourne, Australia</td>
<td>$6,525 (Year 5)</td>
<td>$6,975 (2009–Year 4)</td>
</tr>
<tr>
<td>Nia Kurniati, M.D.</td>
<td>Cipto Mangunkusumo General Hospital</td>
<td>Jakarta, Indonesia</td>
<td>$7,500 (Year 4)</td>
<td>$7,500 (2009–Year 3)</td>
</tr>
<tr>
<td>Kulkanya Chokephaibulkit, M.D.</td>
<td>Mahidol University</td>
<td>Bangkok, Thailand</td>
<td>$10,000 (Year 4)</td>
<td>$5,750 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td>Khu Thi Khanh Dung, Ph.D., M.D.</td>
<td>National Hospital of Pediatrics</td>
<td>Hanoi, Vietnam</td>
<td>$50,000 (Year 4)</td>
<td>$50,000 (2009–Year 4)</td>
</tr>
<tr>
<td>Rawiwan Hansudewechakul, M.D.</td>
<td>Chiang Rai Prachanukroh Hospital</td>
<td>Muang, Thailand</td>
<td>$20,000 (Year 4)</td>
<td>$2,650 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td>Nagalingeswaran Kumasamy, M.D., M.B.B.S.</td>
<td>YRG Centre for AIDS Research and Education</td>
<td>Chennai, India</td>
<td>$7,500 (Year 4)</td>
<td>$9,450 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td>Jintanat Ananworanich, M.D., Ph.D.</td>
<td>HIV-NAT/Thai Red Cross AIDS Research Center</td>
<td>Bangkok, Thailand</td>
<td>$15,000 (2009–Year 3)</td>
<td>$15,000 (Year 4)</td>
</tr>
<tr>
<td>Nia Kurniati, M.D.</td>
<td>Blue Mountains Sexual Health and HIV Clinic</td>
<td>Katoomba, Australia</td>
<td>$1,575 (Year 5)</td>
<td>$1,725 (2009–Year 4)</td>
</tr>
<tr>
<td>Eva Jackson, M.D.</td>
<td>Nepean Hospital</td>
<td>Sydney, Australia</td>
<td>$1,350 (Year 5)</td>
<td>$1,350 (2009–Year 4)</td>
</tr>
<tr>
<td>Mark Kelly, M.B.B.S.</td>
<td>Prince Charles Hospital, AIDS Medical Unit</td>
<td>Brisbane, Australia</td>
<td>$6,300 (Year 5)</td>
<td>$7,350 (2009–Year 4)</td>
</tr>
<tr>
<td>David Nolan</td>
<td>Royal Perth Hospital</td>
<td>Perth, Australia</td>
<td>$7,500 (Year 5)</td>
<td>$7,500 (2009–Year 4)</td>
</tr>
<tr>
<td>Tim Read</td>
<td>Melbourne Sexual Health Centre</td>
<td>Carlton, Australia</td>
<td>$5,550 (Year 5)</td>
<td>$6,075 (2009–Year 4)</td>
</tr>
<tr>
<td>Norman Roth, M.B.B.S., FA.Ch.S.H.M.</td>
<td>Prahran Market Clinic Pty, Ltd.</td>
<td>South Yarra, Australia</td>
<td>$7,125 (Year 5)</td>
<td>$7,500 (2009–Year 4)</td>
</tr>
<tr>
<td>Nia Kurniati, M.D.</td>
<td>Hospital Raja Perempuan Zainab II</td>
<td>Kota Bharu, Malaysia</td>
<td>$7,500 (Year 4)</td>
<td>$7,500 (2009–Year 3)</td>
</tr>
<tr>
<td>Matthew G. Law, Ph.D.</td>
<td>University of New South Wales</td>
<td>Coogee, Australia</td>
<td>$161,157 (Year 4)</td>
<td>$19,000 (2009–Supplemental Funding–Year 3)</td>
</tr>
<tr>
<td>Pagakrong Lumbiganon, M.D.</td>
<td>Khon Kaen University</td>
<td>Khon Kaen, Thailand</td>
<td>$15,000 (Year 4)</td>
<td>$8,000 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td>Fong Siew Moy, M.D.</td>
<td>Hospital Likas</td>
<td>Kota Kinabalu, Malaysia</td>
<td>$7,500 (Year 4)</td>
<td>$7,500 (2009–Year 3)</td>
</tr>
<tr>
<td>Revathy Nallusamy, M.B.B.S.</td>
<td>Penang Hospital</td>
<td>Georgetown, Malaysia</td>
<td>$2,500 (Year 4)</td>
<td>$2,500 (2009–Year 3)</td>
</tr>
<tr>
<td>Sharon Taylor, C.N.C.</td>
<td>Tamworth Sexual Health Service</td>
<td>Tamworth, Australia</td>
<td>$825 (Year 5)</td>
<td>$600 (2009–Year 4)</td>
</tr>
<tr>
<td>Ian Woolley, M.B.B.S., F.R.A.C.P.</td>
<td>Monash Medical Centre–Clayton</td>
<td>Melbourne, Australia</td>
<td>$4,425 (Year 5)</td>
<td>$4,825 (2009–Year 4)</td>
</tr>
<tr>
<td>Lynne Wray, M.B.B.S.</td>
<td>Sydney Sexual Health Centre, Sydney Hospital</td>
<td>Sydney, Australia</td>
<td>$3,675 (Year 5)</td>
<td>$3,675 (2009–Year 4)</td>
</tr>
</tbody>
</table>

### TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TapHOD)

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>City</th>
<th>State</th>
<th>Funding Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jintanat Ananworanich, M.D., Ph.D.</td>
<td>HIV-NAT/Thai Red Cross AIDS Research Center</td>
<td>Bangkok, Thailand</td>
<td>$10,000 (Year 4)</td>
<td>$800 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$15,000 (2009–Year 3)</td>
<td></td>
</tr>
<tr>
<td>Nia Kurniati, M.D.</td>
<td>Cipto Mangunkusumo General Hospital</td>
<td>Jakarta, Indonesia</td>
<td>$7,500 (Year 4)</td>
<td>$3,350 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$7,500 (2009–Year 3)</td>
<td></td>
</tr>
<tr>
<td>Matthew G. Law, Ph.D.</td>
<td>University of New South Wales</td>
<td>Coogee, Australia</td>
<td>$161,157 (Year 4)</td>
<td>$119,665 (2009–Year 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$19,000 (2009–Supplemental Funding–Year 3)</td>
<td></td>
</tr>
<tr>
<td>Pagakrong Lumbiganon, M.D.</td>
<td>Khon Kaen University</td>
<td>Khon Kaen, Thailand</td>
<td>$15,000 (Year 4)</td>
<td>$8,000 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$15,000 (2009–Year 3)</td>
<td></td>
</tr>
<tr>
<td>Fong Siew Moy, M.D.</td>
<td>Hospital Likas</td>
<td>Kota Kinabalu, Malaysia</td>
<td>$7,500 (Year 4)</td>
<td>$7,500 (2009–Year 3)</td>
</tr>
<tr>
<td>Revathy Nallusamy, M.B.B.S.</td>
<td>Penang Hospital</td>
<td>Georgetown, Malaysia</td>
<td>$2,500 (Year 4)</td>
<td>$2,500 (2009–Year 3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nik Khairuldin Nik Yusoff, M.D.</td>
<td>Hospital Raja Perempuan Zainab II</td>
<td>Kota Bharu, Malaysia</td>
<td>$7,500 (Year 4)</td>
<td>$800 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$7,500 (2009–Year 3)</td>
<td></td>
</tr>
<tr>
<td>Kamarul Razali, M.D.</td>
<td>Pediatric Institute, Hospital Kuala Lumpur</td>
<td>Kuala Lumpur, Malaysia</td>
<td>$7,500 (Year 4)</td>
<td>$7,500 (2009–Year 3)</td>
</tr>
<tr>
<td>Virat Sirisanthana, M.D.</td>
<td>Chiang Mai University—Research Institute for Health Sciences</td>
<td>Chiang Mai, Thailand</td>
<td>$15,000 (Year 4)</td>
<td>$1,000 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$15,000 (2009–Year 3)</td>
<td></td>
</tr>
<tr>
<td>Saphonn Vonthonak, M.D.</td>
<td>National Center for HIV/AIDS, Dermatology and STDs</td>
<td>Phnom Penh, Cambodia</td>
<td>$20,000 (Year 4)</td>
<td>$4,400 (Tuberculosis Expansion of Work–Year 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>$20,000 (2009–Year 3)</td>
<td>Funding</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prevalence of HPV and intraepithelial neoplasia biomarkers in adolescents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jintanat Ananworanich, M.D., Ph.D.</td>
<td>HIV-NAT/Thai Red Cross AIDS Research Center</td>
<td>Bangkok, Thailand</td>
<td>$15,000</td>
<td></td>
</tr>
</tbody>
</table>
HIV and HBV co-infection among prenatally HIV-infected adolescents in Asia
Linda Aurpibul, M.D.
Chiang Mai University
Chiang Mai, Thailand
$10,000

Bone mineral density among HIV-infected adolescents
Kulkanya Chokephaibulkit, M.D.
Siriraj Hospital
Mahidol University
Bangkok, Thailand
$15,000

Optimizing HIV treatment for children in Asia: Developing strategies for lifelong Care
Praphan Phanuphak, M.D., Ph.D.
HIV-NAT/Thai Red Cross AIDS Research Center
Bangkok, Thailand
$215,380

Our Village
John Tucker
New Hope for Cambodian Children
Killeen, Texas
$37,320

Building environment for MSM/TG in Cambodia to access friendly health services
Men's Health Social Services
Phnom Penh, Cambodia
$10,000

Advocacy skills and HIV treatment access for MSM and transgender persons
Lao Youth Action Programme under the Lao Buddhist Fellowship Programme
Vientiane, Lao PDR
$10,000

Advocacy to increase resources and mobilize the participation of the MSM community in the HIV response in Vietnam
Institute for Social Development
Hanoi, Vietnam
$9,900

TREAT ASIA QUALITY ASSURANCE SCHEME (TAQAS)
Matthew G. Law, Ph.D.
University of New South Wales
Coogee, Australia
$85,470 (Year 5)
$209,787 (2009–Year 4)

TREAT ASIA STUDIES TO EVALUATE RESISTANCE (TASER)
Rossana Ditangco, M.D.
Asian Foundation for Tropical Medicine, Inc.
Muntinlupa City, Philippines
$82,200 (Year 4)
$66,000 (2009–Year 3)

Adeeba Kamarulzaman, F.R.A.C.P.
University of Malaya
Kuala Lumpur, Malaysia
$62,900 (Year 4)
$66,000 (2009–Year 3)

Pacharee Kantipong, M.D.
Chiang Rai Regional Hospital
Chiang Rai, Thailand
$65,400 (Year 4)
$68,500 (2009–Year 3)

Matthew G. Law, Ph.D.
University of New South Wales
Coogee, Australia
$191,236 (Year 4)
$249,713 (2009–Year 3)

Christopher Lee, M.B.B.S., M.R.C.P.
Sungai Buloh Hospital
Sungai Buloh, Malaysia
$65,400 (Year 4)
$66,000 (2009–Year 3)

Tuti Parwati Merati, M.D.
Udayana University School of Medicine
Denpasar, Indonesia
$62,900 (Year 4)
$66,000 (2009–Year 3)

Mahiran Mustafa, M.D.
Hospital Raja Perempuan Zainab II
Kota Bharu, Malaysia
$60,400 (Year 4)

OTHER RESEARCH FUNDING
Randomized open-label study of second-line combination ART
David Cooper, M.D.
University of New South Wales
Darlinghurst, Australia
$125,000

TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TaP Hod) (Continued)

TREAT ASIA PEDIATRIC HIV OBSERVATIONAL DATABASE (TaP Hod)

TREAT ASIA COMMUNITY PROGRAM AWARDS
Tao Cai
AIDS Care China
Kunming, China
$3,000 (Positive Commitment Award Event Support)
$10,584 (Bridge Funding)
$70,500 (2009–HIV/AIDS Treatment Literacy Training)
2010 MSM Initiative Awards and Community Awards

All projects listed below received awards from amfAR during the period October 1, 2009, to September 30, 2010. Some organizations have requested anonymity to protect the safety of their staff and clients.

MSM INITIATIVE COMMUNITY AWARDS

Africa

The Access Project Extended
Alternatives-Cameroun
Douala, Cameroon
$15,000

Project for STI/HIV Prevention and Care for Highly Vulnerable Populations
Espace Confiance, in collaboration with Sidaction, Paris, France
Abidjan, Côte-d’Ivoire
$9,000

Improving Access to HIV/AIDS Treatment for Mombasa’s MSM Community
PEMA Kenya
Mombasa, Kenya
$10,077

Access Project
Gay and Lesbian Coalition of Kenya, in partnership with Ishtar MSM
Nairobi, Kenya
$13,800

Stop AIDS in Liberia
Monrovia, Liberia
$15,000

Establishment of a Drop-in Centre for MSM in Marrakesh City
Association de Lutte Contre le Sida Marrakesh, Morocco
$15,000

To Support Religious Leaders in Carrying Out Effective HIV and AIDS Responses Targeting MSM and Gay, Bisexual and Transgenders Through Their Faith Communities
South African Network of Religious Leaders Living with or Personally Affected by HIV & AIDS
Johannesburg, South Africa
$15,000

HIV/AIDS Prevention and Treatment Information
Name withheld by request
Kampala, Uganda
$15,000

Sero-prevalence Study for Zambian MSM
Friends of RAINKA
Lusaka, Zambia
$15,750

Asia-Pacific

Promoting Risk Reduction Behaviours Among MSM
Bandhu Social Welfare Society
Dhaka, Bangladesh
$29,998

Legal Support to Chinese Grassroots MSM NGOs in Their HIV-Related Activities
Chengdu Tongle Counseling & Service Center
Chengu, China
$15,000

Field-Based Oral HIV Testing and Linkage to Government Care in a High HIV Prevalence Region of India
Name withheld by request
Secunderabad, India
$29,728

HIV/AIDS Prevention and Support Among Sexually Active MSM in Makassar, South Sulawesi Province, Indonesia
Yayasan Gaya Celebes
Makassar, South Sulawesi, Indonesia
$15,000

HIV Intervention for Hidden MSM Community of Pakistan
Red Ribbon Initiative
Islamabad, Pakistan
$14,975

Transgender Outreach Program
Action for AIDS Singapore
Singapore
$15,980

Expanding HIV Prevention and Outreach Coverage @ Mplus+
Mplus+
Chiang Mai, Thailand
$15,000

MSM Sex Workers in Hanoi: High Risks and Barriers to HIV Prevention
STD/HIV/AIDS Prevention Center
Hanoi, Vietnam
$15,000

Caribbean

Health Empowerment Through Leadership Development and Information
United Belize Advocacy Movement
Belize City, Belize
$15,000

Project “As I Am”
Centro de Orientación e Investigación Integral
Santo Domingo, Dominican Republic
$30,000

Strengthening Community Cohesion and Building Resilience to HIV in Guyana
Society Against Sexual Orientation Discrimination
Georgetown, Guyana
$15,000

Evidence-Based, MSM-Led HIV Prevention and Anti-Stigma Program
Fondation Esther Boucicault Stanislas
Saint-Marc, Haiti
$15,000

Increasing Equitable Access to Prevention for MSM in Haiti
SEROvie
Port-au-Prince, Haiti
$15,000

Bringing Hope, Building Community
Jamaica Forum for Lesbians, All-Sexuals and Gays
Kingston, Jamaica
$15,000

Regional Prevention Response to HIV/AIDS Vulnerability Among MSM Populations in the Caribbean
MSM: No Political Agenda
Santa Cruz, Trinidad and Tobago
$15,000
Eastern Europe and Central Asia

Human Rights Advocacy and HIV/AIDS Prevention, Care, and Support for MSM Communities in Armenia
We For Civil Equality
Yerevan, Armenia
$14,560

HIV Prevention Intervention Among MSM in Chui and Osh Regions of Kyrgyzstan
Public Fund Gender-Vector
Karabalta, Kyrgyzstan
$10,000

Prevention of HIV for MSM Through Information, Peer Counseling, and Community Mobilization and Advocacy
New Life Organization
Orenburg, Russia
$15,000

PULSAR Project: Effective HIV and STI Prevention Among MSM in the Siberian Region
The Siberian Alternative Center
Omsk, Russia
$30,000

Participatory Approach to Evidence-based Planning, Establishing, and Conducting Counseling Centers for MSM
Safe Pulse of Youth
Belgrade, Serbia
$14,980

HIV and Other Socially Significant Diseases Among MSM
CSO Equal Opportunities
Dushanbe, Tajikistan
$15,000

Latin America

Adesproc Libertad GLBT
Asociacion Civil de Desarrollo Social y Promocion Cultural Adesproc Libertad GLBT
La Paz, Bolivia
$7,300

Taking Care of My Life
Asociación Un Nuevo Camino
La Paz, Bolivia
$15,000

Adherence to Treatment, Citizenship and Increasing Incomes of HIV-Positive Transvestites Articulación e Movimiento para Travestis e Transsexuales de Pernambuco
Recife, Brazil
$9,500

Merchants of Illusions Project
Name withheld by request
Recife, Brazil
$10,000

Comprehensive Care for Indigenous MSM Communities affected by HIV/AIDS in the Northern Guajira Peninsula Region of Colombia
Akuaipa Waimakat—Asociación para la Divulgación, Promoción y Defensa de los Derechos Humanos e Indígenas Manaure, Colombia
$13,900

Transgender Incidence
Asociación ALFIL
Quito, Ecuador
$15,000

We Are Healthy
Asociación Solidaria Para Impulsar el Desarrollo Humano (“ASPIDH—ACRO IRIS”)
San Salvador, El Salvador
$14,993

MSM INITIATIVE AWARDS TO COLLABORATING ORGANIZATIONS

Be Heard: Global Forum on MSM and HIV Pre-conference Event—IAC 2010
AIDS Project Los Angeles as secretariat for the Global Forum on MSM and HIV
Los Angeles, CA
$10,000

MSM Against HIV
Colectivo SerGay de Aguascalientes, A.C.
Aguascalientes, Mexico
$15,000

Intervention, Prevention and Testing for MSM in Puerto Vallarta
Vallarta Enfrenta el SIDA, A.C.
Puerto Vallarta, Mexico
$15,000

Case Management: Surveying Adherence to Antiretroviral Treatment for HIV+ MSM in Panamá
Grupo Génesis Panamá Positivo
Panamá City, Panamá
$12,716

Public Policy Awards

All projects listed below were supported by amfAR during the period from October 1, 2009, to September 30, 2010.

Federal Funding for Syringe Exchange
Don Des Jarlais, Ph.D.
Beth Israel Medical Center/Chemical Dependency Institute
New York, NY
$40,000

Syringe Exchange in the U.S., 2009-2010: Assessing a Changing Landscape
Don Des Jarlais, Ph.D.
Beth Israel Medical Center/Chemical Dependency Institute
New York, NY
$75,000

MSM Sexual Health and HIV/STD Prevention: Post-Conference Journal Supplement
Kenneth Mayer, M.D.
The Fenway Institute, Fenway Community Health Center, Inc.
Boston, MA
$10,000
We are pleased to present the audited financial statements of amfAR, The Foundation for AIDS Research, for the fiscal year ending September 30, 2010.

Although the effects of the global economic downturn persisted throughout 2010, amfAR’s prudent financial management and the growing success of its fundraising efforts meant that the organization was able to better its budget projections and end the year with an operating surplus of $2.3 million, more than making up for last year’s $2 million deficit. With public support and revenue rising to $26.4 million, 14 percent above FY09, the Foundation has been able to move forward with long-range plans to expand its research commitments.

amfAR’s operational efficiency and its effective use of donor contributions during 2010 are illustrated by two key figures. The supporting services ratio—the ratio of fundraising and management expenses to total support and revenue—was a low 23.6 percent, while the program spending ratio was a healthy 74.1 percent—meaning that 74 cents out of every dollar spent was invested directly in critical program activities. Program spending was lower in 2010 than in the previous year as a result of careful retrenchment decisions made during the height of the financial crisis in 2009. But this caution, combined with a $2.8 million increase in special events revenues, allowed amfAR to move forward with plans for programmatic expansion in FY2011.

The Foundation’s steady growth in 2010 was accompanied by important programmatic advances. In May 2010, amfAR launched one of the most ambitious and far-reaching research initiatives in its 25-year history. The amfAR Research Consortium on HIV Eradication (ARCHE) announced $1.2 million in grants to four collaborative teams of senior scientists who are actively pursuing a cure for AIDS. amfAR’s commitment to a cure has helped catalyze a surge of interest in cure research, and ARCHE is the centerpiece of its efforts to move this goal forward. TREAT Asia and the MSM Initiative continued to expand their international activities, and amfAR’s public policy office worked tirelessly to promote the needs and protect the rights of people living with HIV and vulnerable to infection.

In 2010, amfAR again met the stringent requirements of governance and financial accountability demanded by the Better Business Bureau’s Wise Giving Alliance and the federal government’s workplace fundraising program, the Combined Federal Campaign, as well as many state employee workplace giving campaigns.

A copy of the complete audited financial statements, prepared in accordance with generally accepted accounting principles for not-for-profit organizations as established by the American Institute of Certified Public Accountants, is available upon request from amfAR at 120 Wall Street, 13th Floor, New York, NY 10005, and can be accessed by visiting www.amfar.org.
Financial Highlights  
For the year ended September 30, 2010

<table>
<thead>
<tr>
<th>Public Support and Revenue</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Public support</td>
<td>$6,531,572</td>
</tr>
<tr>
<td>Special events</td>
<td>9,951,810</td>
</tr>
<tr>
<td>Planned giving</td>
<td>2,541,156</td>
</tr>
<tr>
<td>Government funding</td>
<td>5,959,900</td>
</tr>
<tr>
<td>Investment income and other revenue</td>
<td>1,259,618</td>
</tr>
<tr>
<td><strong>Total public support and revenue</strong></td>
<td><strong>$26,244,056</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Expenses</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$6,365,071</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>5,480,584</td>
</tr>
<tr>
<td>MSM Initiative</td>
<td>1,863,143</td>
</tr>
<tr>
<td>Public Policy</td>
<td>1,569,505</td>
</tr>
<tr>
<td>Public Information</td>
<td>2,445,829</td>
</tr>
<tr>
<td><strong>Total program services</strong></td>
<td><strong>$17,724,132</strong></td>
</tr>
</tbody>
</table>

| Management and general    | 4,232,300 |
| Fundraising               | 1,955,217 |
| Total supporting services | $6,187,517 |

<table>
<thead>
<tr>
<th>Total expenses</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$6,365,071</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>5,480,584</td>
</tr>
<tr>
<td>MSM Initiative</td>
<td>1,863,143</td>
</tr>
<tr>
<td>Public Policy</td>
<td>1,569,505</td>
</tr>
<tr>
<td>Public Information</td>
<td>2,445,829</td>
</tr>
<tr>
<td>Fundraising</td>
<td>4,232,300</td>
</tr>
<tr>
<td>Management and general</td>
<td>1,955,217</td>
</tr>
<tr>
<td><strong>Total expenses</strong></td>
<td><strong>$23,911,649</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Change in net assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets, beginning of year</td>
<td>28,233,359</td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>$30,565,766</td>
</tr>
</tbody>
</table>

Statement of Financial Position

<table>
<thead>
<tr>
<th>Assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and investments</td>
<td>$25,033,610</td>
</tr>
<tr>
<td>Pledges and receivables</td>
<td>9,331,991</td>
</tr>
<tr>
<td>Prepaid expenses and other assets</td>
<td>967,271</td>
</tr>
<tr>
<td>Furniture, equipment, and leasehold improvements</td>
<td>471,557</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$35,804,429</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liabilities</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable and accrued expenses</td>
<td>$1,644,227</td>
</tr>
<tr>
<td>Grants and fellowships payable, net</td>
<td>573,764</td>
</tr>
<tr>
<td>Deferred support and refundable advances</td>
<td>2,679,898</td>
</tr>
<tr>
<td>Other long-term liabilities</td>
<td>340,744</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>$5,238,663</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total net assets</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total liabilities and net assets</td>
<td><strong>$35,804,429</strong></td>
</tr>
</tbody>
</table>
**Expenses**

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fundraising</td>
<td>$4,232,300</td>
</tr>
<tr>
<td>Management and general</td>
<td>$1,955,217</td>
</tr>
<tr>
<td>Program</td>
<td>$17,724,132</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$23,911,649</td>
</tr>
</tbody>
</table>

**Program Expenses**

<table>
<thead>
<tr>
<th>Program</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research</td>
<td>$6,365,071</td>
</tr>
<tr>
<td>TREAT Asia</td>
<td>$5,480,584</td>
</tr>
<tr>
<td>MSM Initiative</td>
<td>$1,863,143</td>
</tr>
<tr>
<td>Public Policy</td>
<td>$1,569,505</td>
</tr>
<tr>
<td>Public Information</td>
<td>$2,445,829</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>$17,724,132</td>
</tr>
</tbody>
</table>
Board of Trustees
Fiscal Year 2010

Chairman of the Board
Kenneth Cole
Chairman
Kenneth Cole Productions
New York, NY

Vice Chairman
Patricia J. Matson
Senior Vice President, Communications (ret.)
ABC, Inc.
New York, NY

Vice Chairman
John C. Simons
Managing Partner
Corporate Fuel Partners LLC
New York, NY

Treasurer
Wallace Sheft, C.P.A.
Partner
Sheft & Co
Westbury, NY

Secretary
Diana L. Taylor
Managing Director
Wolfensohn & Co. LLC
New York, NY

Founding International Chairman
*Dame Elizabeth Taylor
Actress
Bel Air, CA

TRUSTEES

Arlen H. Andelson
Andelson Properties
Los Angeles, CA

Harry Belafonte
President
Belafonte Enterprises, Inc.
New York, NY

David Bohnett
Chairman
David Bohnett Foundation
Beverly Hills, CA

Zev Braun
President and CEO
Braun Entertainment Group, Inc.
Beverly Hills, CA

Jonathan S. Canno
New York, NY

Donald Capoccia
Managing Principal
BFC Partners
Brooklyn, NY

R. Martin Chavez, Ph.D.
Managing Director
Goldman, Sachs & Co.
New York, NY

Jane B. Eisner
President
The Eisner Foundation
Bel Air, CA

Regan Hofmann
Editor-in-Chief
POZ Magazine
New York, NY

Michael J. Klingensmith
CEO and Publisher
Minneapolis Star Tribune
Minneapolis, MN

Michele V. McNeill, Pharm.D.
Chairman
McNeill Family Foundation
Long Boat Key, FL

Richard H. Metzner
Principal
Metzner-Schneider Associates
Dallas, TX

Edward L. Milstein
Co-Chairman
Milstein Brothers Capital Partners
New York, NY

Cindy D. Rachofsky
Philanthropist
Dallas, TX

Vincent A. Roberti
Chairman and CEO
Palisades Media Corp.
New York, NY

Alan D. Schwartz
Executive Chairman
Guggenheim Partners LLC
New York, NY

Mervyn F. Silverman, M.D., M.P.H.
President
Mervyn F. Silverman Associates, Inc.
Crockett, CA

Kevin Wendle
Entrepreneur
New York, NY

ADJUNCT TRUSTEES

David E. Bloom, Ph.D.
Chair, Dept. of Population and International Health
Harvard School of Public Health
Boston, MA

Mario Stevenson, Ph.D.
Director, Center for AIDS Research
University of Massachusetts Medical School
Worcester, MA

TRUSTEES EMERITI

Arthur J. Ammann, M.D.
President, Global Strategies for HIV Prevention
Clinical Professor of Pediatrics
University of California, San Francisco Medical Center
San Rafael, CA

Arnold W. Klein, M.D.
Professor of Medicine/Dermatology
University of California, Los Angeles
Beverly Hills, C
HONORARY TRUSTEES

Mouna E. Ayoub
Paris, France

John F. Breglio, Esq.
Paul, Weiss, Rifkind, Wharton & Garrison
New York, NY

Robert L. Burkett
The Carmen Group
Washington, D.C.

Michael Fuchs
New York, NY

Sandra Hernández, M.D.
Chief Executive Officer
The San Francisco Foundation
San Francisco, CA

Sherry Lansing
Chief Executive Officer/Founder
The Sherry Lansing Foundation
Los Angeles, CA

Jane F. Nathanson
Psychologist
Chair, Jane & Marc Nathanson Community Foundation
Los Angeles, CA

The Rev. Dr. Randolph Nugent
General Secretary (ret.)
General Board of Global Ministries
United Methodist Church
New York, NY

Pauline Phillips
Nationally Syndicated Columnist (ret.)
Los Angeles, CA

Leonard Rabinowitz
President
Studio CL
Los Angeles, CA

Michael D. Shriver
Co-Director, AIDS Policy Research Center
AIDS Research Institute
University of California, San Francisco
San Francisco, CA

Sheldon W. Andelson, Esq.
Mrs. Albert D. Lasker

Jonathan M. Mann, M.D., M.P.H.

Maxine Mesinger
Natasha Richardson
Allan Rosenfield, M.D.

IN MEMORIAM

IN MEMORIAM

Sheldon W. Andelson, Esq.
Mrs. Albert D. Lasker
Jonathan M. Mann, M.D., M.P.H.

Board Development Committee
Chair (vacant)
Zev Braun
Jane B. Eisner
Mathilde Krim, Ph.D.
Patricia J. Matson
Alan D. Schwartz

Compensation and Organizational Development Committee
John C. Simons, Chair
Michael J. Klingensmith
Richard H. Metzner

Finance & Budget Committee
Michael J. Klingensmith, Chair
Vincent A. Roberti
John C. Simons

Fund Development Committee
Vincent A. Roberti, Chair
Jonathan S. Cann0
Edward L. Milstein

BOARDS COMMITTEES

Executive Committee
Kenneth Cole, Chair
Michael J. Klingensmith
Mathilde Krim, Ph.D.
Patricia J. Matson
Wallace Sheft, C.P.A.
Mervyn Silverman, M.D., M.P.H.
John Simons
Diana L. Taylor

Audit Committee
Wallace Sheft, C.P.A., Chair
R. Martin Chavez, Ph.D.
John C. Simons

Executive Committee
Kenneth Cole, Chair
Michael J. Klingensmith
Mathilde Krim, Ph.D.
Patricia J. Matson
Wallace Sheft, C.P.A.
Mervyn Silverman, M.D., M.P.H.
John Simons
Diana L. Taylor

Audit Committee
Wallace Sheft, C.P.A., Chair
R. Martin Chavez, Ph.D.
John C. Simons

Board Development Committee
Chair (vacant)
Zev Braun
Jane B. Eisner
Mathilde Krim, Ph.D.
Patricia J. Matson
Alan D. Schwartz

Compensation and Organizational Development Committee
John C. Simons, Chair
Michael J. Klingensmith
Richard H. Metzner

Finance & Budget Committee
Michael J. Klingensmith, Chair
Vincent A. Roberti
John C. Simons

Fund Development Committee
Vincent A. Roberti, Chair
Jonathan S. Cann0
Edward L. Milstein
Scientific Advisory Committee

Mario Stevenson, Ph.D. (Chair)
Director, Center for AIDS Research
University of Massachusetts Medical School
Worcester, MA

Sherry Deren, Ph.D. (Co-Chair)
Director, Center for Drug Use and HIV Research
Senior Research Scientist
New York University College of Nursing

Deborah Anderson, Ph.D.
Professor and Director
Division of Reproductive Biology
Boston University School of Medicine

Warren A. Andiman, M.D.
Professor of Pediatrics, Epidemiology and Public Health
Department of Pediatrics
Yale University School of Medicine

Jose Arturo Bauermeister, M.P.H., Ph.D.
Research Assistant Professor
Department of Health Behavior and Health Education
University of Michigan

Michael Belshan, Ph.D.
Assistant Professor
Department of Medical Microbiology and Immunology
Creighton University

Jason Brenchley, Ph.D.
Tenure-Track Investigator
Laboratory of Molecular Microbiology
National Institute of Allergy and Infectious Diseases, National Institutes of Health

Dennis R. Burton, Ph.D.
Professor
Department of Immunology
The Scripps Research Institute

Salvatore T. Butera, D.V.M., Ph.D.
Chief
Virology Section
Centers for Disease Control and Prevention

Edward Campbell, Ph.D.
Assistant Professor
School of Medicine
Loyola University Chicago

Alex Carballo-Dieguez, Ph.D.
Research Scientist and Professor of Clinical Psychology
Department of Psychology
Columbia University

Larry Williams Chang, M.D., Ph.D.
Department of Medicine
Johns Hopkins University

David B. Clifford, M.D.
Professor
Department of Neurology
Washington University School of Medicine

Eric Cohen, Ph.D.
Research Unit Director
Institut de recherches cliniques de Montréal

C. Budd Colby, Ph.D.
Colby Biomedical Consultants

Grant Colfax, M.D.
Director of HIV Prevention and Research
San Francisco Department of Public Health

Deborah Jean Cotton, M.D., M.P.H.
Professor of Medicine
Department of Medicine
Boston University School of Medicine

Bryan Richard Cullen, Ph.D.
Professor
Department of Genetics
Duke University Medical Center

Susanna Cunningham-Rundles, Ph.D.
Professor of Immunology
Department of Pediatrics
Cornell University Medical College

Richard Thomas D’Aquila, M.D.
Addison B. Scoville Professor of Medicine
Department of Medicine
Vanderbilt University School of Medicine

Ronald C. Desrosiers, Ph.D.
Professor of Microbiology and Molecular Genetics
Harvard Medical School

Roger Detels, M.D., M.S.
Professor of Epidemiology
School of Public Health
University of California, Los Angeles

Carl W. Dieffenbach, Ph.D.
Director, Basic Sciences Program
Division of AIDS
National Institute of Allergy and Infectious Diseases, National Institutes of Health

Daniel C. Douek, M.D., Ph.D.
Chief, Human Immunology Section
Vaccine Research Center
National Institute of Allergy and Infectious Diseases, National Institutes of Health

D. Peter Drotman, M.D., M.P.H.
Editor-in-Chief
Emerging Infectious Diseases
Centers for Disease Control and Prevention

Anke A. Ehrhardt, Ph.D.
Director and Professor
Department of Psychiatry
Columbia University

Homayoon Farzadegan, Ph.D.
Professor
Department of Epidemiology
Johns Hopkins University

Dianne M. Finkelstein, Ph.D.
Director of Biostatistics
Cancer Center Biostatistics
Massachusetts General Hospital and Harvard Medical School

Alan Frankel, Ph.D.
Professor
Department of Biochemistry and Biophysics
University of California, San Francisco

Gerald Herbert Friedland, M.D.
Professor and Director, AIDS Program
Department of Internal Medicine
Yale School of Medicine

Victor Garcia-Martinez, Ph.D.
Professor of Medicine, School of Medicine
Center for Infectious Diseases
University of North Carolina, Chapel Hill

Howard E. Gendelman, M.D.
David T. Purtilo Professor of Pathology and Microbiology
Department of Pathology and Microbiology
University of Nebraska Medical Center

Stephen P. Goff, Ph.D.
Higgins Professor of Microbiology & Immunology
Biochemistry & Molecular Biophysics
Howard Hughes Medical Institute
Columbia University

Nancy L. Haigwood, Ph.D.
Director and Senior Scientist
Division of Pathobiology & Immunology
Oregon National Primate Research Center

Dean Hamer, Ph.D.
Senior Investigator and Head
Gene Structure and Regulation Section
National Cancer Institute, National Institutes of Health

Daria Hazuda, Ph.D.
Vice President of Virus and Cell Biology
Department of Antiretroviral Research, Molecular Endocrinology, Virus and Cell Support, and Medicinal Chemistry
Merck Research Laboratories

Charles H. Hinkin, Ph.D.
Associate Professor
Department of Psychiatry and Biobehavioral Science
University of California School of Medicine

David Ho, M.D.
Scientific Director, Chief Executive Officer
Aaron Diamond AIDS Research Center

Thomas J. Hope, Ph.D.
Professor
Department of Cell and Molecular Biology
Northwestern University Feinberg School of Medicine

Keith J. Horvath, Ph.D.
Assistant Professor
School of Public Health
University of Minnesota

Shiu-Lok Hu, Ph.D.
Professor
School of Pharmacy
University of Washington

Kuan Teh Jeang, Ph.D.
Chief
Medical Virology Section
National Institute for Allergy and Infectious Diseases, National Institutes of Health
Program Advisory Council

Mervyn Silverman, M.D., M.P.H. (Chairman)
President
Mervyn F. Silverman Associates, Inc.

David Bloom, Ph.D. (Co-chairman)
Chair, Department of Global Health and Population
Harvard School of Public Health

Mario Stevenson, Ph.D. (Co-chairman)
Professor of Medicine, Chief, Division of Infectious Diseases
University of Miami
Leonard M. Miller School of Medicine

Tim Brown, Ph.D.
Senior Fellow
The East-West Center

Lishan Su, Ph.D.
Associate Professor
Department of Microbiology and Immunology
University of North Carolina-Chapel Hill

Ernest F. Terwilliger, Ph.D.
Assistant Professor
Beth Israel Deaconess Medical Center

Barbara Visscher, M.D., Dr.P.H.
Professor of Epidemiology
Department of Epidemiology
University of California, Los Angeles

David Vlahov, Ph.D.
Director
Center for Urban Epidemiologic Studies
New York Academy of Medicine

David J. Volsky, Ph.D.
Professor and Director
Department of Pathology and Medicine
St. Luke’s-Roosevelt Hospital Center and Columbia University

Mark A. Wainberg, Ph.D.
Professor and Director
McGill AIDS Centre
McGill University

Daria J. Hazuda, Ph.D.
Vice President
Worldwide Franchise Discovery Head for Antivirals
Merck & Company, Inc.

Kenneth H. Mayer, M.D.
Professor of Medicine and Community Health
Brown University, Alpert Medical School
Infectious Diseases Division
The Miriam Hospital
Medical Research Director
Fenway Health

Jeffrey L. Sturchio, Ph.D.
President and Chief Executive Officer
The Global Health Council

Management Group

Kevin Robert Frost
Chief Executive Officer

Anthony Ancona
Vice President and Director, Human Resources

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Gregory Boroff, C.A.E., C.F.R.E.
Vice President and Director, Development

Chris Collins, M.P.P.
Vice President and Director, Public Policy

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

John F. Logan, Ph.D., J.D.
Vice President and General Counsel

AnnMari Shannahan
Vice President, Public Information

Annette Sohn, M.D.
Vice President and Director, TREAT Asia

Steven S. Witkin, Ph.D.
Professor and Director
Department of Obstetrics and Gynecology
Weil Medical College of Cornell University

Peter R. Wolfe, M.D.
Los Angeles, California

Richard T. Wyatt, Ph.D.
Professor of Immunology
International AIDS Vaccine Initiative Center for Neutralizing Antibodies
Scripps Research Institute

Xiao-Fang Yu, M.D., D.Sc.
Professor
Department of Molecular Microbiology and Immunology
Bloomberg School of Public Health
Johns Hopkins University

Ann M. Sheehy, Ph.D.
Assistant Professor
Biology Department
College of the Holy Cross

Frederick P. Siegal, M.D.
Chief, Section of HIV Medicine and Medical Director
Department of Medicine
Saint Vincent’s Hospital and Medical Center

Gail Skowron, M.D.
Associate Professor of Medicine
Department of Medicine, Division of Infectious Diseases
Roger Williams Medical Center

Leonidas Stamatatos, Ph.D.
Full Member and Director of Viral Vaccines Program
Seattle Biomedical Research Institute

Klaus Strebel, Ph.D.
Chief, Viral Biochemistry Section
Laboratory of Molecular Microbiology
National Institute of Allergy and Infectious Diseases, National Institutes of Health

Susan J. Blumenthal, M.D., M.P.A.
Senior Policy and Medical Advisor

Gregory Boroff, C.A.E., C.F.R.E.
Vice President and Director, Development

Chris Collins, M.P.P.
Vice President and Director, Public Policy

Bradley Jensen
Chief Financial Officer

Rowena Johnston, Ph.D.
Vice President and Director, Research

Jeffrey Laurence, M.D.
Senior Scientific Consultant for Programs

John F. Logan, Ph.D., J.D.
Vice President and General Counsel

AnnMari Shannahan
Vice President, Public Information

Annette Sohn, M.D.
Vice President and Director, TREAT Asia

Steven S. Witkin, Ph.D.
Professor and Director
Department of Obstetrics and Gynecology
Weil Medical College of Cornell University

Peter R. Wolfe, M.D.
Los Angeles, California

Richard T. Wyatt, Ph.D.
Professor of Immunology
International AIDS Vaccine Initiative Center for Neutralizing Antibodies
Scripps Research Institute

Xiao-Fang Yu, M.D., D.Sc.
Professor
Department of Molecular Microbiology and Immunology
Bloomberg School of Public Health
Johns Hopkins University

Lishan Su, Ph.D.
Associate Professor
Department of Microbiology and Immunology
University of North Carolina-Chapel Hill

Ernest F. Terwilliger, Ph.D.
Assistant Professor
Beth Israel Deaconess Medical Center

Barbara Visscher, M.D., Dr.P.H.
Professor of Epidemiology
Department of Epidemiology
University of California, Los Angeles

David Vlahov, Ph.D.
Director
Center for Urban Epidemiologic Studies
New York Academy of Medicine

David J. Volsky, Ph.D.
Professor and Director
Department of Pathology and Medicine
St. Luke’s-Roosevelt Hospital Center and Columbia University

Mark A. Wainberg, Ph.D.
Professor and Director
McGill AIDS Centre
McGill University

Daria J. Hazuda, Ph.D.
Vice President
Worldwide Franchise Discovery Head for Antivirals
Merck & Company, Inc.

Kenneth H. Mayer, M.D.
Professor of Medicine and Community Health
Brown University, Alpert Medical School
Infectious Diseases Division
The Miriam Hospital
Medical Research Director
Fenway Health

Jeffrey L. Sturchio, Ph.D.
President and Chief Executive Officer
The Global Health Council